Natixis Advisors, L.P. Roivant Sciences Ltd. Transaction History
Natixis Advisors, L.P.
- $54.1 Billion
- Q1 2025
A detailed history of Natixis Advisors, L.P. transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 36,433 shares of ROIV stock, worth $424,444. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,433
Previous 51,620
29.42%
Holding current value
$424,444
Previous $611,000
39.77%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ROIV
# of Institutions
345Shares Held
495MCall Options Held
3.67MPut Options Held
754K-
Qvt Financial LP New York, NY65.8MShares$766 Million69.8% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X061.9MShares$721 Million5.69% of portfolio
-
Viking Global Investors LP46MShares$536 Million1.55% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.8MShares$475 Million0.01% of portfolio
-
Morgan Stanley New York, NY35.9MShares$419 Million0.03% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.21B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...